Scholarlink

Background <p>Data on cognition in adult patients with myelin oligodendrocyte glycoprotein antibody-associated disease (pwMOGAD) are scarce.</p> Objective <p>To examine cognitive function in pwMOGAD and assess relative risks (RR) for cognitive impairment (CImp) in pwMOGAD relative to healthy controls (HC), aquaporin 4-immunoglobulin G positive neuromyelitis optica spectrum disorders (pwAQP4+NMOSD), and double-seronegative NMOSD (pwdsNMOSD) compared to HC.</p> Methods <p>Data derived from a cohort with neuroimmunological disorders. Cognitive performance was assessed using Rao’s brief repeatable battery of neuropsychological tests, compared to HC using confounder-adjusted linear regressions. CImp was defined as performing two standard deviations below the HC mean in any subtest. RR for CImp was calculated using generalized linear models.</p> Results <p>We evaluated cognitive performance of 21 pwMOGAD and 25 HC. CImp was additionally determined in 43 pwAQP4+NMOSD and 15 pwdsNMOSD. PwMOGAD performed worse on Selective Reminding Test, and the symbol digit modalities test compared to HC. Adjusted RR for CImp were 1.9 (95% CI 0.9–4.1) in pwMOGAD, 1.9 (95% CI 1.0–3.9) in pwAQP4+NMOSD and 2.1 (95% CI 0.9–4.6) in pwdsNMOSD.</p> Conclusion <p>pwMOGAD performed worse in information processing speed, verbal learning, storage and retrieval compared to HC. RR for CImp in pwMOGAD compared to HC was similar to that estimated for pwAQP4+NMOSD and pwdsNMOSD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cognitive function in patients with myelin oligodendrocyte glycoprotein antibody-associated disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月6日

查看全文
  • Rebekka Rust,
  • Susanna Asseyer,
  • Patrick Schindler,
  • Claudia Chien,
  • Sophia Rekers,
  • Carsten Finke,
  • Frederike Cosima Oertel,
  • Klemens Ruprecht,
  • Sven Jarius,
  • Brigitte Wildemann,
  • Velina Chavarro,
  • Tanja Schmitz-Hübsch,
  • Friedemann Paul,
  • Pia Sophie Sperber

摘要

Background

Data on cognition in adult patients with myelin oligodendrocyte glycoprotein antibody-associated disease (pwMOGAD) are scarce.

Objective

To examine cognitive function in pwMOGAD and assess relative risks (RR) for cognitive impairment (CImp) in pwMOGAD relative to healthy controls (HC), aquaporin 4-immunoglobulin G positive neuromyelitis optica spectrum disorders (pwAQP4+NMOSD), and double-seronegative NMOSD (pwdsNMOSD) compared to HC.

Methods

Data derived from a cohort with neuroimmunological disorders. Cognitive performance was assessed using Rao’s brief repeatable battery of neuropsychological tests, compared to HC using confounder-adjusted linear regressions. CImp was defined as performing two standard deviations below the HC mean in any subtest. RR for CImp was calculated using generalized linear models.

Results

We evaluated cognitive performance of 21 pwMOGAD and 25 HC. CImp was additionally determined in 43 pwAQP4+NMOSD and 15 pwdsNMOSD. PwMOGAD performed worse on Selective Reminding Test, and the symbol digit modalities test compared to HC. Adjusted RR for CImp were 1.9 (95% CI 0.9–4.1) in pwMOGAD, 1.9 (95% CI 1.0–3.9) in pwAQP4+NMOSD and 2.1 (95% CI 0.9–4.6) in pwdsNMOSD.

Conclusion

pwMOGAD performed worse in information processing speed, verbal learning, storage and retrieval compared to HC. RR for CImp in pwMOGAD compared to HC was similar to that estimated for pwAQP4+NMOSD and pwdsNMOSD.